About this trial
This study aims to investigate the value of 18F-FDG and 68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of advanced colorectal cancer (peritoneal metastasis with/without other metastases)
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Histologically confirmed colorectal cancer, clinical or other imaging suspicion of peritoneal metastasis with or without other distant metastases.
Patients voluntarily enrolled in this study by signing an informed consent form
Age ≥ 18 years
Expected life expectancy ≥ 3 months
Disqualifiers
Pregnant or breastfeeding women.
Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix
Severe mental disease, uncontrolled epilepsy, or central nervous system disease
Subjects with current concurrent interstitial pneumonitis or interstitial lung disease, or subjects with previous interstitial pneumonitis or interstitial lung disease requiring hormonal therapy, or subjects with other conditions that may interfere with the judgement and management of immune-related pulmonary toxicity, e.g., pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pneumoconiosis, Drug-associated pneumonia, idiopathic pneumonia, active pneumonia, or severe pulmonary impairment on CT; and active tuberculosis
Trial population
Eligible inpatients and outpatients from Ruijin Hospital
Trial design
Other
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Diagnostic accuracy
18F-FDG and 68Ga-FAPI PET/CT was used to diagnose the lesions of the patients, and the diagnostic performance of PET/CT was evaluated by comparing the diagnostic results with the pathological results/clinical evaluation results.
Standardized uptake value(SUV)
SUV of 68Ga-FAPI and 18F-FDG uptake on PET/CT images for tumor lesions
Target-to-background ratio(TBR)
68Ga-FAPI and 18F-FDG uptake ratio of tumor lesions to mediastinum and liver blood pool on PET/CT images.
Secondary outcomes
Progress free survival
Progress free survival
Overall survival
Overall survival
Sponsors and contacts
Click on the lead sponsor to view all of their trials.